{
    "id": 26649,
    "fullName": "EGFR L833F",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR L833F lies within the protein kinase domain of the Egfr protein (UniProt.org). L833F has been identified in the scientific literature (PMID: 26762747, PMID: 25130612), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 9126,
                    "pubMedId": 26762747,
                    "title": "Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26762747"
                },
                {
                    "id": 8112,
                    "pubMedId": 25130612,
                    "title": "Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25130612"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "L833F",
    "createDate": "06/13/2017",
    "updateDate": "10/06/2019",
    "referenceTranscriptCoordinates": {
        "id": 135762,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55191748G>T",
        "cDna": "c.2499G>T",
        "protein": "p.L833F",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16528,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L833F were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 27921,
                "profileName": "EGFR L833F"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16527,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L833F were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 27921,
                "profileName": "EGFR L833F"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16529,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L833F were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 27921,
                "profileName": "EGFR L833F"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11162,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, non-small cell lung cancer patients harboring EGFR L833F demonstrated a response rate of 0% and disease control rate of 100%, and a median progression-free survival of 4.2 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).",
            "molecularProfile": {
                "id": 27921,
                "profileName": "EGFR L833F"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9121,
                    "pubMedId": null,
                    "title": "Clinical efficacy of icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 18, 20 and 21 uncommon mutations.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_186649.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17722,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung cancer co-harboring EGFR L833F and EGFR L858R demonstrated a partial response when treated with Gilotrif (afatinib) (PMID: 31043566).",
            "molecularProfile": {
                "id": 32753,
                "profileName": "EGFR L833F EGFR L858R"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15696,
                    "pubMedId": 31043566,
                    "title": "Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31043566"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27921,
            "profileName": "EGFR L833F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32753,
            "profileName": "EGFR L833F EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135762,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55191748G>T",
            "cDna": "c.2499G>T",
            "protein": "p.L833F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}